Phaseline

Companies › Clear Scientific

Clear Scientific: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Other, Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CS-1103
Opioid receptor antagonist
–Phase 2Fentanyl Overdose; Methamphetamine Intoxication–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07459166CS-1103Phase 2Fentanyl OverdoseOtherJul 2026
NCT06721494CS-1103Phase 2Methamphetamine IntoxicationPsychiatryOct 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Syndeio Biosciences Tonix Pharmaceuticals Adneuris Therapeutics Angitia Zynerba Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.